Skip to main content

Innovations in Review 2025

Cardiology & Heart Surgery

In 2025, cardiologists and cardiac surgeons at NewYork-Presbyterian led breakthroughs that impacted a range of diseases and conditions from advanced heart failure to pediatric valve disease. Physicians and researchers from Columbia and Weill Cornell Medicine pioneered the use of artificial intelligence to identify structural heart disease, launched a mobile app to expand access to heart failure education, performed one of the first split-root domino partial heart transplants, and more. Our experts remained at the forefront of innovative, multidisciplinary care, delivering comprehensive treatment for the most complex cardiac diseases.

Cardiology and Heart Surgery
Cardiology and Heart Surgery

Download the Full Report  View the E-booklet

Read more about our top research and key innovations from 2025:

Study Shows Ability Of AI Screening Tool To Detect Structural Heart Disease

5-Year Outcomes Show PCI Can Be As Effective As Bypass In Treating CAD

LVAD Therapy Offers Survival Outcomes Similar To Heart Transplant In Younger HF Patients

Integrated Team Performs New York’s First Heart-Lung-Liver Transplant

New Mobile App Makes Heart Failure Education More Accessible

Split-Root Domino Partial Heart Transplant Saves Three Pediatric Patients

Novel Remote Monitoring Device May Detect Heart Failure Events Earlier

GLP-1s Provide New Options To Manage Heart Disease

Advancing Cardiology And Heart Surgery Through Collaboration

Developing Precise Diagnostics For Hypertrophic Cardiomyopathy

Study Shows Ability Of AI Screening Tool To Detect Structural Heart Disease

A new deep learning model could accurately identify structural heart disease on electrocardiogram (ECG) readings more frequently than cardiologists, including those who use AI to assist in interpreting the data. Pierre Elias, M.D., a cardiologist at NewYork-Presbyterian and Columbia and medical director for artificial intelligence at NewYork-Presbyterian, led a team of physicians and researchers in developing and validating EchoNext, a convolutional neural network model trained on more than 1.2 million ECG-echocardiogram pairs from 230,000 patients. It accurately identified 77% of structural heart problems, compared to 64% for cardiologists on non–AI-assisted reviews and 69% for AI-assisted ones. This data is supporting the use of AI to improve screening access and early detection.

Read more
Study Shows Ability Of Ai Screening Tool To Detect Structural Heart Disease

5-Year Outcomes Show PCI Can Be As Effective As Bypass In Treating CAD

Five-year outcomes from the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial show, for the first time, the non-inferiority of percutaneous coronary intervention (PCI) compared to coronary artery bypass grafting (CABG) in treating three-vessel coronary artery disease not involving the left main coronary artery. In a paper coauthored by Yuhei Kobayashi, M.D., an interventional cardiologist at NewYork-Presbyterian and Weill Cornell Medicine and director of interventional cardiology research at NewYork-Presbyterian Brooklyn Methodist, results from the international FAME 3 trial indicated no significant difference between PCI and CABG on a composite measure of death, stroke, or myocardial infarction. These results help give cardiologists more confidence to recommend PCI to patients who want a minimally invasive option to treat severe coronary artery disease.

Read more
5-Year Outcomes Show PCI Can Be As Effective As Bypass In Treating CAD

LVAD Therapy Offers Survival Outcomes Similar To Heart Transplant In Younger HF Patients

Receiving a left ventricular assist device (LVAD) may be as effective at prolonging life as undergoing a heart transplant for younger patients with heart failure, according to a comparative data analysis from the MOMENTUM 3 trial. Led by Nir Uriel, M.D., MSc, director of heart failure, cardiac transplantation, and mechanical circulatory support at NewYork-Presbyterian, the study results showed that, at two years, survival rates for both LVAD patients and heart transplant patients were about 90% after propensity score matching. These findings offer support for advanced treatment strategies that start a younger patient on LVAD therapy as a bridge to transplant for net prolongation of life.

Read more
LVAD Therapy Offers Survival Outcomes Similar To Heart Transplant In Younger HF Patients

Integrated Team Performs New York’s First Heart-Lung-Liver Transplant

A multidisciplinary transplant team at NewYork-Presbyterian and Columbia performed the first heart-lung-liver transplant in New York on a patient with pulmonary arterial hypertension, heart failure, and congestive liver cirrhosis. The 14-hour surgery required months of preparation to develop a transplant and post-surgical care plan tailored to the patient’s complex condition. The team’s careful coordination demonstrated how skill, collaboration, and surgical and medical integration are leading to more successful outcomes in multiorgan transplantation.

Read more
Integrated Team Performs New York’s First Heart-Lung-Liver Transplant

New Mobile App Makes Heart Failure Education More Accessible

Recognizing the need for a comprehensive, centralized resource for heart failure research and education, David Majure, M.D., MPH, medical director of the heart transplant service at NewYork-Presbyterian and Weill Cornell Medicine, launched a mobile app called NYP Advances that includes trial information, a video library for continuing medical education, and a journal watch covering research conducted by NewYork-Presbyterian physicians. Developed in collaboration with members of NewYork-Presbyterian’s Heart Failure Research Institute, which includes specialists from both Columbia and Weill Cornell Medicine, the NYP Advances app offers vital information in a condensed and user-friendly format.

Read more
The NYP Advances app is the only comprehensive mobile source for in-depth analysis of literature and data on heart failure

Split-Root Domino Partial Heart Transplant Saves Three Pediatric Patients

A multidisciplinary pediatric heart transplant team at NewYork-Presbyterian Morgan Stanley Children’s Hospital of Children’s Hospital of New York, led by Andrew Goldstone, M.D., Ph.D., surgical director of heart transplant and mechanical circulatory support and pediatric heart valve transplantation at NewYork-Presbyterian and Columbia, is among the first in the nation to perform a split-root domino partial heart transplant. This series of surgeries allowed a pediatric recipient of a donor heart to donate her healthy aortic and pulmonary valves to two other children with congenital heart conditions. Physicians and surgeons see the success of the surgery as progress toward innovative solutions to treating pediatric valve disease and are exploring ways to expand opportunities for living heart valve donation.

Read more
From left: John, Hend, and Teddy, the three patients who were part of the split-root domino.

Novel Remote Monitoring Device May Detect Heart Failure Events Earlier

The current standard of care for remote monitoring of heart failure events relies on blood pressure measurements, which can have a lag time of up to 10 days for accurate indications, potentially leading to significant complications and delays. To address this issue, Nir Uriel, M.D., MSc, director of heart failure, cardiac transplantation, and mechanical circulatory support at NewYork-Presbyterian, led an early feasibility study to evaluate a new device that monitors changes in the size of the inferior vena cava to relay information about blood volume. This novel approach is allowing doctors to detect fluid buildup and potentially improve quality of care for patients.

Watch here
Novel Remote Monitoring Device May Detect Heart Failure Events Earlier

GLP-1s Provide New Options To Manage Heart Disease

With increasing use of GLP-1 medications, research is expanding to investigate their potential applications beyond diabetes and weight loss. On the Advances in Care podcast, David Majure, M.D., MPH, medical director of the heart transplant service at NewYork-Presbyterian and Weill Cornell Medicine, discussed the molecular mechanisms of GLP-1s and their potential cardiovascular benefits. Dr. Majure, a leader in the field, has researched several studies that examine the effects of semaglutide and tirzepatide on patients with heart failure, particularly those with preserved ejection fraction. The impact of GLP-1s on outcomes such as hospitalization and cardiovascular death is guiding the way for more advanced research and application of these medications for patients suffering from heart disease.

Listen here
GLP-1s Provide New Options To Manage Heart Disease

Advancing Cardiology And Heart Surgery Through Collaboration

For more than 40 years, Craig Smith, M.D., former surgeon-in-chief at NewYork-Presbyterian and Columbia, has made significant contributions to the field of cardiac surgery. His achievements include inaugurating the heart-lung transplantation program at the institution and coleading the crucial PARTNER clinical trials, which demonstrated the success of transcatheter aortic valve replacement (TAVR), now the gold standard for treating aortic stenosis. On the Advances in Care podcast, Dr. Smith shared his perspective on the evolution of cardiac surgery and transplantation, discussed innovations in surgical technology that are transforming the future of care, and emphasized the vital role of a multidisciplinary heart team in achieving optimal patient outcomes.

Listen here
Advancing Cardiology And Heart Surgery Through Collaboration

Developing Precise Diagnostics For Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disorder and one of the leading causes of sudden death in young adults. In an episode of the Advances in Care podcast, Diala Steitieh, M.D., director of the Hypertrophic Cardiomyopathy Program at NewYork-Presbyterian and Weill Cornell Medicine, addressed the current challenges of diagnosing HCM with conventional imaging and detailed her research on goal-directed Valsalva, a novel diagnostic protocol that is enhancing treatment plans. She also discussed recent updates to the management of HCM, including approved drugs and new guidelines regarding sports and exercise. This research is helping advance early detection and diagnostics to improve quality of life for patients with this condition.

Listen here
Advances in Care with Dr. Diala Steitieh